-+ 0.00%
-+ 0.00%
-+ 0.00%

CE-Ventures backs Aptadir Therapeutics in €40 million seed round

PUBT·09/30/2026 10:27:09
CE-Ventures backs Aptadir Therapeutics in €40 million seed round
  • Crescent Enterprises’ CE-Ventures invested in Aptadir Therapeutics in a EUR 40 million seed round announced Sept. 29, 2026.
  • Aptadir is a preclinical biotech developing RNA inhibitor-based therapeutics designed to reverse abnormal gene silencing in genetic disorders.
  • Proceeds target clinical advancement of lead program CAP1-FMR1 for Fragile X Syndrome, expansion across genetic disorders, oncology programs.
  • Financing ranks as Italy’s largest biotech seed round, among Europe’s largest, strengthening CE-Ventures’ life sciences exposure to RNA therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Enterprises Venture Capital published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.